NICE is unable to make a recommendation on teduglutide (Revestive) for short bowel syndrome in people 1 year and over because Takeda withdrew its evidence submission. Another company has confirmed that it wishes to make a new submission for the appraisal.

Guidance development process

How we develop NICE technology appraisal guidance

  • National Institute for Health and Care Excellence (NICE)